WuXi PharmaTech Inks New Pact To Synthesize Compounds For AstraZeneca
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Shanghai-headquartered WuXi PharmaTech, one of China's leading contract research organizations, this week signed a new agreement to synthesize compounds according to AstraZeneca's designs
You may also be interested in...
AstraZeneca Shares Its Recipe For Partnering Success In Asia
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
AstraZeneca Shares Its Recipe For Partnering Success In Asia
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
Venturepharm Rides Chinese Wave Of CRO Growth; Sees Challenges Ahead As Competition Among MNCs, Locals Increase
HONG KONG - The growth of contract research organizations in China has been little short of astounding. China has overtaken India as one of the fastest-growing locations for drug trials, leveraging a huge population and Western-trained doctors into a competitive industry